How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy?
Despite the presence of APOMut in cell-associated HIV-DNA GRTs, virologic suppression was maintained in PLWH switching to PAIT. Virologic failures were unrelated to the presence of APOMut. These results suggest that APOMuts should not be considered in the management of ART.
Authors
- Romane Guilbaud
- Valentine Marie Ferré (ORCID: https://orcid.org/0000-0002-2196-6141)
- Jade Ghosn (ORCID: https://orcid.org/0000-0003-2914-959X)
- Quentin Le Hingrat (ORCID: https://orcid.org/0000-0001-9017-4941)
- Diane Descamps (ORCID: https://orcid.org/0000-0002-6556-1525)
- M Digumber
- Gilles Peytavin (ORCID: https://orcid.org/0000-0002-4359-537X)
- Marie Gilbert
- Yazdan Yazdanpanah
- Véronique Joly
- Charlotte Charpentier
Institutions
- Délégation Paris 5 (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre d'Immunologie et des Maladies Infectieuses (FR)
- Hôpital Bichat-Claude-Bernard (FR)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-09-08
- DOI
- https://doi.org/10.1093/jac/dkaf353
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00